BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 24499755)

  • 1. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices.
    Aoun J; Dines VA; Stovall DW; Mete M; Nelson CB; Gomez-Lobo V
    Obstet Gynecol; 2014 Mar; 123(3):585-592. PubMed ID: 24499755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of age and parity with intrauterine device expulsion.
    Madden T; McNicholas C; Zhao Q; Secura GM; Eisenberg DL; Peipert JF
    Obstet Gynecol; 2014 Oct; 124(4):718-726. PubMed ID: 25198262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications and continuation of intrauterine device use among commercially insured teenagers.
    Berenson AB; Tan A; Hirth JM; Wilkinson GS
    Obstet Gynecol; 2013 May; 121(5):951-958. PubMed ID: 23635730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
    Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
    Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study.
    Phillips SJ; Hofler LG; Modest AM; Harvey LFB; Wu LH; Hacker MR
    Am J Obstet Gynecol; 2017 Jul; 217(1):57.e1-57.e6. PubMed ID: 28315664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
    Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
    Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of intrauterine devices among young women: a systematic review.
    Jatlaoui TC; Riley HEM; Curtis KM
    Contraception; 2017 Jan; 95(1):17-39. PubMed ID: 27771475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intrauterine devices in nulliparous women.
    Lohr PA; Lyus R; Prager S
    Contraception; 2017 Jun; 95(6):529-537. PubMed ID: 27591814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
    Nilsson CG; Allonen H; Diaz J; Luukkainen T
    Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review.
    Foran T; Butcher BE; Kovacs G; Bateson D; O'Connor V
    Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):379-386. PubMed ID: 30382754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expulsion and continuation rates of the 52 mg levonorgestrel intrauterine system in adolescents and adult women.
    Brull E; Machado HC; Bahamondes L; Juliato CRT
    Eur J Contracept Reprod Health Care; 2023 Aug; 28(4):210-215. PubMed ID: 37335234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical carcinogenesis and contraception.
    Misra JS; Engineer AD; Das K; Tandon P
    Diagn Cytopathol; 1991; 7(4):346-52. PubMed ID: 1935511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.